Skip to main content
. 2020 Dec 3;41(1):6–16. doi: 10.1177/0333102420973994

Figure 2.

Figure 2.

Monthly and overall rates of reversion from chronic migraine to episodic migraine during the double-blind treatment phase.

*p < 0.001 compared with placebo.

p = 0.003 compared with placebo.

Odds ratio (95% CI) versus placebo.